Dr. Larson on Ongoing Trials in Colorectal Cancer

Tim G. Larson, MD
Published: Thursday, Nov 09, 2017



Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

The BEACON trial is looking at patients with BRAF mutations, which is a small subset of patients with CRC who have a poor prognosis and do not respond to the standard treatments. This trial is offering these patients promising therapies, says Larson.

A different phase III trial is examining the effectiveness of napabucasin (BBI-608), an oral cancer stem cell inhibitor, in the second-line setting.
SELECTED
LANGUAGE


Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

The BEACON trial is looking at patients with BRAF mutations, which is a small subset of patients with CRC who have a poor prognosis and do not respond to the standard treatments. This trial is offering these patients promising therapies, says Larson.

A different phase III trial is examining the effectiveness of napabucasin (BBI-608), an oral cancer stem cell inhibitor, in the second-line setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x